NASDAQ: APRE
Aprea Therapeutics Inc Stock Ownership - Who owns Aprea Therapeutics?

Insider buying vs selling

Have Aprea Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Oren GiladPresidentCEO2025-04-033,003$1.87
$5.62kBuy
Oren GiladPresidentCEO2025-04-032,497$1.80
$4.49kBuy
Oren GiladPresidentCEO2024-10-23500$3.92
$1.96kBuy
Marc DueyDirector2024-10-186,462$4.58
$29.58kSell
Marc DueyDirector2024-10-1630,000$4.39
$131.70kBuy
Oren GiladPresidentCEO2024-10-15250$2.90
$725.00Buy
Marc DueyDirector2024-10-14190$2.58
$490.20Buy
Oren GiladPresidentCEO2024-10-141,000$2.59
$2.59kBuy
John P. HamillSrVPCFOPrin Fin Acct Ofcr2024-10-1150$2.46
$123.20Buy
Bernd R. SeizingerDirector2024-10-1110,000$2.68
$26.80kBuy

1 of 2

APRE insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when APRE insiders and whales buy or sell their stock.

APRE Shareholders

What type of owners hold Aprea Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Tryant LLC506.20%28,000,000$50.40MInsider
Thomas Banks242.09%13,391,146$24.10MInsider
Frank J. Hall86.45%4,781,889$8.61MInsider
David West Wilson52.88%2,924,726$5.26MInsider
Heidi A. Patterson48.60%2,688,221$4.84MInsider
Kdev Investments Ab36.02%1,992,586$3.59MInsider
Michael Reynolds35.80%1,980,040$3.56MInsider
Redmile Group LLC31.98%1,768,718$3.18MInsider
Aigh Capital Management LLC9.75%539,300$970.74kInstitution
Oren Gilad6.28%347,420$625.36kInsider

1 of 3

APRE vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
APRE3.18%96.82%Net Buying
IMNN2.34%63.55%Net Buying
CELZ7.80%1.36%Net Selling
IMRN0.00%0.00%
EVGN6.31%0.00%

Aprea Therapeutics Stock Ownership FAQ

Who owns Aprea Therapeutics?

Aprea Therapeutics (NASDAQ: APRE) is owned by 35.25% institutional shareholders, 1,073.76% Aprea Therapeutics insiders, and 0.00% retail investors. Tryant LLC is the largest individual Aprea Therapeutics shareholder, owning 28.00M shares representing 506.20% of the company. Tryant LLC's Aprea Therapeutics shares are currently valued at $52.64M.

If you're new to stock investing, here's how to buy Aprea Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.